Search

Search Constraints

You searched for: Author/Creator Benn, Paul

Search Results

1. 833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results. (4th December 2021)

2. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. (1st October 2022)

5. LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials. (31st December 2020)

6. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Issue 10267 (19th December 2020)

7. O023 Feasibility study to determine the time taken for NAATs tests to become negative following treatment for Chlamydia trachomatis and Neisseria gonorrhoeae in men and women. (30th June 2016)